Welcome to our dedicated page for Immix Biopharma news (Ticker: IMMX), a resource for investors and traders seeking the latest updates and insights on Immix Biopharma stock.
Immix Biopharma, Inc. develops clinical-stage cell therapies focused on relapsed/refractory AL Amyloidosis, led by NXC-201, a sterically optimized BCMA-targeted CAR-T therapy. Company news commonly covers NXC-201 clinical data from the NEXICART-2 study, FDA designations such as Breakthrough Therapy, RMAT and orphan-drug status, and regulatory-development planning.
Updates also include equity financings, pre-funded warrants, private placements, investor-conference participation, and commercial and medical leadership additions tied to the company’s rare-disease oncology and hematology strategy.
Immix Biopharma (IMMX) closed a $150 million underwritten registered offering of common stock, selling 16,778,524 shares at $8.94 per share.
According to Immix Biopharma, net proceeds were about $140.65 million. The financing included leading U.S. biotechnology institutional investors and mutual funds.
Immix Biopharma (NASDAQ: IMMX) priced an underwritten registered offering of 16,778,524 common shares at $8.94 per share, for expected gross proceeds of $150 million.
Net proceeds will fund NXC-201 development, working capital and general corporate purposes, supporting operations into mid‑2028, subject to closing around May 22, 2026.
Immix Biopharma (IMMX) reported an interim update from its relapsed/refractory AL Amyloidosis trial NEXICART-2.
The NXC-201 therapy shows a 95% complete response (CR) rate (19/20 patients), with all CRs achieved within 1 year, no relapses among CR patients to date, and all later patients with available data MRD-negative at one month. A multi-center randomized Phase 3 in newly diagnosed patients is planned, with the next NEXICART-2 update expected in late September 2026 and 1-year follow-up data targeted by end of March 2027.
Immix Biopharma (NASDAQ:IMMX) will participate in the Jefferies Global Healthcare Conference June 2-4, 2026 in New York.
The company said it will host one-on-one institutional investor meetings and that a replay link will be posted to its Presentation & Events page on the investor website when available.
Immix Biopharma (NASDAQ:IMMX) announced completion of enrollment in its BLA‑enabling NEXICART‑2 trial for relapsed/refractory AL amyloidosis, meeting prior guidance. Topline NEXICART‑2 results are expected in Q3 2026, followed by a planned BLA submission and intended commercial launch.
The company also appointed Dr. Richard Graydon as Chief Medical Officer; Dr. Graydon has led new and supplemental drug and biologics applications at Merck and Johnson & Johnson for multiple approved therapies.
Immix Biopharma (NASDAQ:IMMX) will present and host investor meetings at two institutional conferences in Miami Beach in March 2026. Management will attend the Leerink Partners 2026 Global Healthcare Conference March 8–11 and Citizens Life Sciences Conference March 10–11, 2026.
One-on-one meetings are available via conference representatives; replay links will be posted on the company Presentation & Events page when available.
Immix Biopharma (NASDAQ: IMMX) announced that the U.S. FDA has granted Breakthrough Therapy Designation to NXC-201 for relapsed/refractory AL amyloidosis based on positive NEXICART-2 Phase 2 interim results presented at ASH on December 7, 2025. Final NEXICART-2 data are expected in 2026, with a planned BLA submission this year. Management said the designation recognizes NXC-201 as the only FDA breakthrough granted among therapies in active development for this indication and reiterated plans to complete enrollment and pursue regulatory filing.
Immix Biopharma (NASDAQ:IMMX) announced the closing of an upsized underwritten registered offering on Dec 9, 2025 consisting of 19,117,646 shares of common stock at $5.10 per share and 490,196 pre-funded warrants at $5.09 each.
Net proceeds to the company after underwriting discounts, commissions and offering expenses were approximately $93.7 million. The financing included leading U.S. biotechnology institutional investors and mutual funds, with Morgan Stanley as sole book‑running manager and Citizens Capital Markets and Mizuho as co‑managers.
The securities were offered under a shelf registration statement (Form S-3, File No. 333-269100) declared effective Jan 11, 2023; a prospectus supplement was filed with the SEC and is available on the SEC website.
Immix Biopharma (NASDAQ:IMMX) priced an underwritten offering of 19,117,646 common shares at $5.10 each and pre-funded warrants to purchase 490,196 shares at $5.09 per warrant, for expected gross proceeds of $100 million.
The offering is expected to close on or about December 9, 2025, subject to customary closing conditions. Immix intends to use net proceeds to fund NXC-201 development, working capital and general corporate purposes, and says cash plus expected CIRM grant disbursements should fund operations into mid-2027. Morgan Stanley is sole book-runner; Citizens Capital Markets and Mizuho are co-managers. Securities are offered under a Form S-3 shelf registration.
Immix Biopharma (NASDAQ:IMMX) reported positive Phase 2 results for NXC-201 at ASH 2025 with an independent review committee complete response (CR) rate of 75% (15/20) at s/u IFE(-).
MRD negativity in bone marrow was observed in 4 of 5 pending patients, which the company says could raise the CR to 95%. Downstream organ responses occurred in 70% of evaluable patients (7/10). No neurotoxicity and only low-grade cytokine release syndrome (median duration 1 day) were reported. NEXICART-2 final readout and planned BLA submission in 2026. Data cutoff: Nov 13, 2025.